High Growth US Tech Stocks To Watch In May 2025

The United States market has shown robust performance with a 4.5% rise over the last week and an 11% increase in the past year, supported by an anticipated annual earnings growth of 14%. In this favorable environment, identifying high growth tech stocks that align with these positive trends can be key to capitalizing on potential opportunities.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	26.28%	37.43%	★★★★★★
Ardelyx	20.57%	59.97%	★★★★★★
Travere Therapeutics	25.75%	64.53%	★★★★★★
Blueprint Medicines	21.36%	61.45%	★★★★★★
TG Therapeutics	25.99%	38.42%	★★★★★★
Alnylam Pharmaceuticals	23.65%	61.11%	★★★★★★
AVITA Medical	27.28%	60.66%	★★★★★★
Alkami Technology	20.54%	76.67%	★★★★★★
Ascendis Pharma	35.16%	60.26%	★★★★★★
Lumentum Holdings	21.59%	110.32%	★★★★★★

Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Alnylam Pharmaceuticals (NasdaqGS:ALNY)

Simply Wall St Growth Rating: ★★★★★★

Overview: Alnylam Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutics utilizing ribonucleic acid interference technology and has a market capitalization of approximately $34.89 billion.

Operations: Alnylam Pharmaceuticals generates revenue primarily from the discovery, development, and commercialization of RNAi therapeutics, amounting to $2.35 billion. The company leverages ribonucleic acid interference technology as a core component of its business model.

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is demonstrating significant strides in its sector with a projected annual revenue growth of 23.7% and earnings growth forecast at 61.1%. The company's commitment to innovation is underscored by its R&D expenses which are substantial, reflecting its focus on developing treatments for conditions like ATTR amyloidosis with cardiomyopathy. Recent approvals of AMVUTTRA® for ATTR-CM in the U.S. and Brazil highlight their progress and potential market impact. Moreover, Alnylam's recent presentation at the Heart Failure 2025 Congress further solidifies its position as a pioneer in addressing rare diseases through advanced RNAi therapies, promising enhanced patient outcomes with fewer doses per year.

• Navigate through the intricacies of Alnylam Pharmaceuticals with our comprehensive health report here.

• Gain insights into Alnylam Pharmaceuticals' historical performance by reviewing our past performance report.

Netflix (NasdaqGS:NFLX)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Netflix, Inc. is a leading provider of entertainment services with a market capitalization of approximately $489.83 billion.

Operations: The company generates revenue primarily from its streaming entertainment service, which brought in $40.17 billion.

Netflix, amidst a bustling tech landscape, is charting a robust growth trajectory with its revenue expected to surge by 10.2% annually, outpacing the U.S. market's 8.6%. This growth is complemented by an impressive forecast of annual earnings increase at 15.6%, signaling strong operational efficiency and market adaptability. The company's strategic emphasis on R&D is evident from its substantial investment in innovation, crucial for sustaining its competitive edge in the streaming and content creation sectors. Recent executive transitions and shareholder proposals indicate a dynamic corporate governance environment that could influence future strategies and investor relations.

• Unlock comprehensive insights into our analysis of Netflix stock in this health report.

• Gain insights into Netflix's past trends and performance with our Past report.

Palo Alto Networks (NasdaqGS:PANW)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Palo Alto Networks, Inc. offers cybersecurity solutions globally and has a market capitalization of approximately $126.39 billion.

Operations: The company generates revenue primarily from its Security Software & Services segment, which accounts for $8.57 billion.

Palo Alto Networks has demonstrated robust growth in the high-tech sector, with a notable 12.8% forecasted annual revenue increase and an impressive 17.8% expected earnings growth per year, outpacing the U.S. market's average. Recent strategic partnerships, like with T-Mobile for enhanced 5G security solutions and Deloitte for AI-driven cybersecurity enhancements, underscore its innovative approach in integrating cutting-edge technologies to address complex security challenges. The company's commitment to R&D is evident from its significant investments aimed at advancing cybersecurity solutions across various platforms, ensuring it remains at the forefront of technological evolution and enterprise security.

• Click here and access our complete health analysis report to understand the dynamics of Palo Alto Networks.

• Review our historical performance report to gain insights into Palo Alto Networks''s past performance.

Seize The Opportunity

• Access the full spectrum of 233 US High Growth Tech and AI Stocks by clicking on this link.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com